A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

NCT03220347 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

139

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Lymphoma, Non-Hodgkin
Neoplasms

Interventions

DRUG: CC-90010

Sponsor

Celgene